Chemotherapy and Cancer Pharmacology

Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era

Platinum-based chemotherapy remains a cornerstone in the treatment of platinum-sensitive ovarian cancer (PSOC) due to its demonstrated efficacy in prolonging progression-free survival (PFS).1-3 Retreatment with platinum agents, especially in patients who have been exposed to poly ADP-ribose polymerase inhibitors (PARPi) presents challenges with respect to both efficacy and toxicity. Recently, novel targeted therapies, including antibody-drug… Continue reading Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era

Study reveals activity of navtemadlin in glioblastoma, points to possible treatment improvements

Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy. Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in… Continue reading Study reveals activity of navtemadlin in glioblastoma, points to possible treatment improvements

Making Biliary Tract Cancer Treatment More Precise

Tumors arising in the gallbladder, bile ducts, and the small intestine are collectively referred to as biliary tract cancers. These cancers are rare—affecting approximately 12,350 individuals in 2024—but they are typically diagnosed at advanced stages when surgery, which can improve prognosis, is no longer an option. Angela Lamarca, MD, PhD Systemic therapies, therefore, are the… Continue reading Making Biliary Tract Cancer Treatment More Precise

Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL

Following positive results from a clinical trial, the immunotherapy drug blinatumomab (Blincyto) is expected to become part of the standard initial treatment for many kids with B-cell acute lymphoblastic leukemia, the most common form of childhood cancer.

VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial

TROPION-Breast01 (NCT05104866) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) with the TROP2-directed ADC Dato-DXd vs investigator’s choice of CT (ICC) in patients (pts) with previously treated, inoperable/metastatic HR+/HER2– BC (HR 0.63 [95% CI 0.52–0.76]; p<0.0001). We report the final OS analysis and updated safety.

A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

This phase 1 study demonstrated that LY3295668 erbumine, a highly selective, orally bioavailable, and reversible Aurora kinase A inhibitor, both as monotherapy and in combination with standard chemotherapy in children with relapsed/refractory neuroblastoma, had a manageable safety profile. Despite robust preclinical data, relatively modest clinical activity (two partial responses and two minor responses with combination… Continue reading A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy

Abstract Background Alterations in mismatch repair (MMR) genes like MLH1, MSH2, MSH6, and PMS2 can lead to microsatellite instability–high (MSI-H) tumors. These mutations can be inherited, as in Lynch syndrome (LS), or occur de novo. Although immune checkpoint inhibitors (ICI) improves survival in MSI-H colorectal cancer (CRC) compared to chemotherapy, data comparing outcomes for patients with… Continue reading Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy

Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505

Abstract Background Chemotherapy is required to improve the overall survival (OS) of patients with resectable pancreatic ductal adenocarcinoma (PDAC). Assessing the impact of chemotherapy dose density (DD) on survival is difficult as a result of confounding. The objective of this study was to determine the impact of chemotherapy DD on OS in patients with resectable… Continue reading Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505

Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505

A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma